CD8A and breast carcinoma: Samples were available from all 6 patients (five baseline, six surgery; five paired; Supplementary Table S4) and were stained to detect cytokeratin 7 to determine breast cancer cells, PD-L1 expression, and changes in CD8 effector T cells recruited by the combined immunotherapy.